6.54BMarket Cap-41604P/E (TTM)
120.150High117.450Low617.62KVolume119.160Open117.650Pre Close73.74MTurnover1.17%Turnover RatioLossP/E (Static)54.62MShares126.96052wk High14.52P/B6.33BFloat Cap59.22052wk Low--Dividend TTM52.85MShs Float126.960Historical High--Div YieldTTM2.30%Amplitude14.250Historical Low119.396Avg Price1Lot Size
Glaukos Stock Forum
$Arcutis Biotherapeutics(ARQT.US)$ :
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co(MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos(GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co(MRK.US)$ : Approved ...
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics(CRSP.US)$ $Vertex Pharmaceuticals(VRTX.US)$ $OptiNose(OPTN.US)$ $Arcutis Biotherapeutics(ARQT.US)$ $Calliditas Therapeutics(CALT.US)$ $bluebird bio(BLUE.US)$ $Glaukos(GKOS.US)$ $Ionis Pharmaceuticals(IONS.US)$ $Amgen(AMGN.US)$ $Merck & Co(MRK.US)$
im seeing some decent chart upside here
thoughts?
$SciSparc(SPRC.US)$ rallied Wednesday, climbing over 20%, after the Israeli pharmaceuticals company said the psychedelic-based MEAI drug candidate developed with Canadian collaborator Clearmind Medicine produced a significant decrease in coccaine craving in rats compared to those in a non-treated control group during pre-clinical testing.
$Glaukos(GKOS.US)$ gained 6% after We...
• $Canoo(GOEV.US)$ +71.3% (receives purchase order of 4500 Canoo Electric Delivery Vehicles from Walmart)
• $Aldeyra Therapeutics(ALDX.US)$ +14.1% (achieved primary endpoints in dry eye disease chamber crossover clinical trial)
• $Westport Fuel(WPRT.US)$ +10.9% (awarded 38 mln program)
• $Greenwich LifeSciences(GLSI.US)$ +5.9% (FDA has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed...
No comment yet